Skip to Content
Merck
All Photos(1)

Key Documents

MAB2241

Sigma-Aldrich

Anti-Tau Antibody, clone Tau 12

clone Tau 12, from mouse

Synonym(s):

G protein beta1/gamma2 subunit-interacting factor 1, Neurofibrillary tangle protein, Paired helical filament-tau, microtubule-associated protein tau, microtubule-associated protein tau, isoform 4

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified antibody

clone

Tau 12, monoclonal

species reactivity

human

technique(s)

western blot: suitable

isotype

IgG1κ

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

General description

Microtubule Associated Proteins, or MAPS, bind to the tubulin subunits of microtubule structures and regulate their functional stability. In the cell MAPs bind to monomer and multimerized tubulin. MAP binding to multimerized tubulin further stabilizes the formation of higher order microtubulin structures. MAP binding to microtubule structures is mediated through phosphorylation through Microtubule Affinity Regulated Kinase (MARK). Phosphorylation releases MAPs bound to microtubules, destabilizing the structure, driving it toward disassembly. There are predominately two MAP types, I, II. Type II MAP includes MAP2, MAP4, and tau and are found in nervous tissue. Six tau isoforms exist in brain tissue, and they are distinguished by their number of binding domains. Three isoforms have three binding domains and the other three have four binding domains. The binding domains are located in the carboxy-terminus of the protein and are positively-charged (allowing it to bind to the negatively-charged microtubule). The isoforms with four binding domains are better at stabilizing microtubules than those with three binding domains.

Specificity

Cat. # MAB2241 recognizes the N-terminus region of Tau.
Reactivity with other species has not been determined.

Immunogen

Epitope: N-terminus
KLH conjugated synthetic linear peptide.

Application

Anti-Tau Antibody, clone Tau 12 is an antibody against Tau for use in WB.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases

Quality

Western Blot:

Target description

50-68 kDa

Linkage

Replaces: MAB10417

Physical form

Format: Purified
Protein G Purified
Purified in 0.1M Tris-Glycine (pH7.4) 150mM NaCl with 0.05% NaN3.

Storage and Stability

Stable for 1 year at 2-8ºC from date of receipt.

Analysis Note

Control
Human brain tissue lysate.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Michael J Ellis et al.
Acta neuropathologica, 147(1), 87-87 (2024-05-18)
Antibodies are essential research tools whose performance directly impacts research conclusions and reproducibility. Owing to its central role in Alzheimer's disease and other dementias, hundreds of distinct antibody clones have been developed against the microtubule-associated protein Tau and its multiple
Hiroki Takeuchi et al.
NPJ vaccines, 5, 28-28 (2020-03-29)
Pathological aggregates of tau proteins accumulate in the brains of neurodegenerative tauopathies including Alzheimer's disease and frontotemporal lobar degeneration (FTLD-tau). Although immunotherapies of these disorders against tau are emerging, it is unknown whether nasal delivery, which offers many benefits over
Juan Ramón Perea et al.
Experimental neurology, 310, 14-21 (2018-08-24)
Tauopathies are a broad set of neurodegenerative dementias characterized by the aggregation of Tau protein. Activated microglia and elevated levels of pro-inflammatory molecules are also pathological hallmarks of tauopathies. In these diseases, intracellular Tau is secreted to the extracellular space
Francesc X Guix et al.
International journal of molecular sciences, 19(3) (2018-03-03)
Progressive cerebral accumulation of tau aggregates is a defining feature of Alzheimer's disease (AD). A popular theory that seeks to explain the apparent spread of neurofibrillary tangle pathology proposes that aggregated tau is passed from neuron to neuron. Such a
April L Darling et al.
Protein science : a publication of the Protein Society, 30(7), 1350-1359 (2021-03-10)
Alzheimer's disease is a progressive fatal neurodegenerative disease with no cure or effective treatments. The hallmarks of disease include extracellular plaques and intracellular tangles of aggregated protein. The intracellular tangles consist of the microtubule associated protein tau. Preventing the pathological

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service